Matrixyl: The Collagen Signal Peptide in Your Serum
Cosmetic Peptides
3 ppm
In a 12-week, double-blind, placebo-controlled trial of 93 women, pal-KTTKS reduced wrinkles and fine lines at a concentration of just 3 parts per million, 0.0003% of the formulation.
Robinson et al., Int J Cosmet Sci, 2005
Robinson et al., Int J Cosmet Sci, 2005
View as imageIn 2000, the French cosmetic ingredient company Sederma launched a synthetic pentapeptide under the trade name Matrixyl. The peptide, palmitoyl-KTTKS (lysine-threonine-threonine-lysine-serine with a 16-carbon fatty acid attached), was derived from a fragment of human type I procollagen. The concept was simple: when collagen breaks down in aging skin, the resulting peptide fragments signal fibroblasts to produce new collagen. Matrixyl is an artificial version of that breakdown signal, designed to trick skin cells into repairing damage that may or may not have occurred. Among cosmetic peptides, it belongs to the "signal peptide" category, distinct from neurotransmitter-inhibiting peptides like argireline that target muscle contraction. For a full breakdown of cosmetic peptide categories, see Every Type of Cosmetic Peptide: Signal, Carrier, Neurotransmitter, and Enzyme Inhibitor.
Two and a half decades later, Matrixyl appears in thousands of anti-aging products. Its manufacturer-funded clinical trial showed statistically significant wrinkle reduction at 3 ppm, a concentration so low it raised eyebrows in the field.[1] The in vitro data on collagen stimulation is consistent across multiple labs.[2] But the independent clinical evidence remains thin, the concentrations used in commercial products are rarely disclosed, and the gap between what fibroblasts do in a dish and what happens in intact human skin is substantial.
Key Takeaways
- Matrixyl (pal-KTTKS) is a synthetic pentapeptide modeled on a fragment of type I procollagen, designed to signal fibroblasts to increase collagen production (Lupo and Cole, Dermatologic Therapy, 2007)
- In a 12-week RCT of 93 women, 3 ppm pal-KTTKS in a moisturizer significantly reduced wrinkles versus placebo by quantitative image analysis and expert grading (Robinson et al., Int J Cosmet Sci, 2005)
- C16-KTTKS stimulates collagen production in dermal fibroblasts in a concentration-dependent manner linked to its self-assembly into nanotape structures at the critical aggregation concentration (Jones et al., Mol Pharm, 2013)
- An 8-week RCT found pal-KTTKS cream reduced crow's feet wrinkle scores by 0.86 points with zero adverse events, outperforming both acetyl hexapeptide-3 and placebo (Errante et al., J Clin Aesthet Dermatol, 2023)
- KTTKS analogues with modified amino acid sequences show variable effects on fibroblast viability and matrix metalloproteinase activity, suggesting the native sequence has a narrow structure-activity window (Talalaj et al., Molecules, 2019)
- The KTTKS sequence occurs naturally in the C-terminal propeptide of type I procollagen, acting as a matrikine that regulates extracellular matrix turnover during wound healing and tissue remodeling (Sivaraman and Shanthi, Life Sciences, 2018)
Where the KTTKS Sequence Comes From
The five-amino-acid sequence KTTKS (Lys-Thr-Thr-Lys-Ser) is not a synthetic invention. It exists naturally in the C-terminal propeptide of type I procollagen, the precursor molecule that fibroblasts secrete before it is processed into mature collagen fibers. When enzymes called procollagen C-proteinases cleave the propeptide during collagen maturation, they release peptide fragments into the extracellular space. These fragments, called matrikines, act as signaling molecules that regulate new matrix production.[3]
Matrikines are a broader class of bioactive peptides derived from extracellular matrix protein degradation. They differ from their parent proteins in function: collagen is structural, but the fragments produced by its breakdown are informational. Sirois and Heinz (2024) cataloged matrikines from collagen, elastin, fibronectin, and laminins, noting that each ECM protein produces fragments with distinct biological activities.[4] The KTTKS fragment specifically stimulates fibroblasts to upregulate synthesis of collagens I, III, and IV, as well as fibronectin and glycosaminoglycans.[5]
The commercial product adds a palmitoyl group (a 16-carbon saturated fatty acid) to the N-terminus of KTTKS. This lipid tail serves two purposes: it increases the peptide's lipophilicity, theoretically improving penetration through the stratum corneum's lipid-rich barrier, and it anchors the peptide in cell membranes where its receptor targets reside. The resulting molecule, C16-KTTKS or palmitoyl pentapeptide-4, has a molecular weight of approximately 802 Da. For comparison, the copper peptide GHK-Cu, another signal peptide that stimulates collagen at picomolar concentrations, has a molecular weight of just 403 Da.[6] For more on copper peptide mechanisms, see How Copper Peptides Stimulate Collagen: Mechanism Explained.
The Clinical Evidence
The Robinson 2005 Trial
The landmark study on pal-KTTKS was a 12-week, double-blind, placebo-controlled, split-face trial conducted by Robinson and colleagues, funded by Procter & Gamble (the licensee of Matrixyl for consumer products).[1] The trial enrolled 93 Caucasian women aged 35 to 55. Each subject applied a moisturizer containing 3 ppm pal-KTTKS to one side of her face and an identical moisturizer without the peptide to the other side, twice daily for 12 weeks.
The results: pal-KTTKS produced statistically significant reduction in wrinkles and fine lines compared to the placebo moisturizer, as assessed by both quantitative digital image analysis and expert graders. The peptide was well tolerated with no adverse events reported.
Three ppm is 0.0003%. To put that in perspective, retinol is typically used at 0.025% to 1%, and vitamin C at 5% to 20%. The claimed activity of pal-KTTKS at concentrations three to four orders of magnitude below these established actives is remarkable. It also makes the clinical result difficult to verify independently, because at such low concentrations, the margin between active and inactive formulations is razor-thin.
The study's limitations are worth noting: it was manufacturer-funded, the specific magnitude of wrinkle improvement was reported as "significant" without clear effect sizes in percentage terms, and the 3 ppm concentration makes it nearly impossible to distinguish peptide effects from vehicle effects unless the study design is airtight.
The Errante 2023 Crow's Feet Trial
A more recent trial by Errante and colleagues (2023) compared pal-KTTKS cream (0.005%) head-to-head against acetyl hexapeptide-3 (argireline) cream and placebo for periorbital crow's feet.[7] This double-blind, randomized trial enrolled 21 Indonesian women aged 26 to 55 (Fitzpatrick types III-V) and ran for 8 weeks.
Results: pal-KTTKS reduced crow's feet grading scores by 0.86 points on both static and dynamic measures. Five of seven subjects (71.4%) rated the cosmetic outcome as "very good." Critically, the pal-KTTKS group reported zero complaints, while the argireline group experienced itching, stinging, and burning.
The pal-KTTKS group also demonstrated decreases in fold depth (18%), fold thickness (37%), and improvements in skin firmness (21%) over 28 days in the cited prior data. These numbers come from earlier manufacturer studies rather than the Errante trial itself, a distinction that is easy to miss.
The trial's main weakness: 7 subjects per group is too small to draw firm conclusions. The results are directionally consistent with the Robinson data but do not constitute strong independent confirmation.
Mechanism: How Pal-KTTKS Stimulates Collagen
In Vitro Evidence
Jones and colleagues (2013) provided the most mechanistically detailed study of C16-KTTKS in the peer-reviewed literature.[2] They exposed human dermal fibroblasts and corneal fibroblasts to C16-KTTKS solutions and measured collagen output.
The findings: C16-KTTKS stimulated collagen production in a concentration-dependent manner. The collagen-stimulating effect correlated with the peptide's self-assembly behavior. At concentrations near the critical aggregation concentration (CAC), the peptide forms nanotape structures, elongated ribbon-like assemblies visible by transmission electron microscopy. The researchers proposed that this self-assembly is not incidental but functionally important: the organized nanotape presentation may be required for effective receptor engagement.
This is a meaningful finding. If the peptide must self-assemble to work, then concentration matters in a non-linear way. Below the CAC, the peptide is monomeric and potentially inactive. Above it, the peptide organizes into structures that present the KTTKS motif in a specific geometry. Formulation choices that disrupt this self-assembly (surfactants, pH changes, competing molecules) could neutralize the peptide's activity entirely.
The Matrikine Signaling Model
The broader framework for understanding pal-KTTKS comes from matrikine biology. Sivaraman and Shanthi (2018) reviewed matrikines across the extracellular matrix, noting that collagen-derived fragments activate fibroblasts through specific membrane receptors, triggering intracellular signaling cascades that upregulate ECM gene expression.[3]
Jariwala and colleagues (2024) used computational screening to identify novel tetrapeptide matrikines from ECM proteins, finding that even small changes in peptide sequence dramatically alter biological activity.[8] This is consistent with work by Talalaj et al. (2019), who synthesized KTTKS analogues with modified amino acids and found that most modifications reduced or eliminated the peptide's ability to stimulate collagen while altering cytotoxicity and matrix metalloproteinase interactions.[9] The native KTTKS sequence appears to occupy a narrow structure-activity optimum.
Matrixyl vs. Matrixyl 3000 vs. Matrixyl Synthe'6
Sederma has released three generations of Matrixyl products, and the naming creates confusion.
Matrixyl (original) is palmitoyl pentapeptide-4 (pal-KTTKS), the subject of this article. It is a single peptide that signals collagen production.
Matrixyl 3000 is a combination of two different peptides: palmitoyl tripeptide-1 (pal-GHK) and palmitoyl tetrapeptide-7 (pal-GQPR). Pal-GHK is the palmitoylated form of the GHK sequence that also appears in copper peptide research. Pal-GQPR targets interleukin-6 to reduce inflammation-driven matrix degradation. The combination is designed to stimulate collagen production while simultaneously reducing inflammatory breakdown.
Matrixyl Synthe'6 contains palmitoyl tripeptide-38, a peptide designed to mimic the thrombospondin-1 sequence and stimulate synthesis of six major matrix components: collagen I, III, and IV, fibronectin, hyaluronic acid, and laminin.
These are three different products with different peptide compositions, but they share a trade name. A product labeled "contains Matrixyl" could contain any of the three. The clinical data from the Robinson 2005 trial applies only to the original pal-KTTKS, not to Matrixyl 3000 or Synthe'6. Each formulation has its own evidence base, and the evidence for the newer versions is even thinner than for the original.
The Penetration Problem
Pal-KTTKS has a molecular weight of approximately 802 Da. The widely cited "500 Dalton rule" in dermatology suggests that molecules above 500 Da penetrate the stratum corneum poorly. The palmitoyl group was added specifically to improve penetration by increasing lipophilicity, but whether this is sufficient remains debated.
Gorouhi and Maibach (2009) reviewed the penetration evidence for topical peptides broadly and concluded that most cosmeceutical peptides face significant delivery challenges.[5] The stratum corneum is a formidable barrier: 15 to 20 layers of flattened, dead corneocytes embedded in a lipid matrix of ceramides, cholesterol, and free fatty acids. A peptide must navigate this hydrophobic environment, survive enzymatic degradation by skin proteases, and reach viable fibroblasts in the dermis at sufficient concentration to trigger a biological response.
Pai et al. (2017) noted that while in vitro studies consistently show collagen stimulation, the concentrations used in cell culture are applied directly to fibroblasts with no barrier.[10] The gap between what a peptide does when placed directly on cells versus what it does when applied to the surface of intact skin is the central unresolved question in cosmetic peptide science. For how this penetration challenge affects Do Peptide Serums Actually Work? What Clinical Studies Show.
Skibska and Perlikowska (2021) reviewed delivery strategies for signal peptides in cosmetics, including liposomal encapsulation, microemulsions, and microneedling-assisted delivery.[11] These approaches may improve penetration but add complexity and cost, and most commercial Matrixyl products use simple aqueous or oil-in-water formulations.
Where Matrixyl Fits in the Evidence Landscape
Matrixyl occupies an unusual position among cosmetic peptides. Its mechanism is well-supported by in vitro data: the KTTKS sequence derives from collagen, matrikine signaling is a validated biological pathway, and multiple labs have confirmed collagen stimulation in fibroblast cultures. The structure-activity data from KTTKS analogues supports the specificity of the native sequence.
The clinical evidence is positive but limited. Two controlled trials (n=93 and n=21) show wrinkle reduction, both with methodological caveats. The concentrations tested (3 ppm and 0.005%) are remarkably low. No large-scale, independently funded clinical trial has been published.
By comparison, argireline has a larger clinical evidence base but a different mechanism (neurotransmitter inhibition rather than collagen signaling). SNAP-8, an eight-amino-acid extension of argireline, targets the same SNARE complex pathway. Both belong to the neurotransmitter-inhibiting peptide class. The two approaches, signal peptides and neurotransmitter inhibitors, are sometimes combined in products, targeting wrinkles through complementary pathways. For a broader comparison of cosmetic peptide approaches and their evidence, see Do Peptide Serums Actually Work?.
What sets Matrixyl apart from many cosmeceutical ingredients is the biological plausibility. The matrikine concept, that collagen breakdown products signal repair, is not marketing fiction. It is an established biological process with decades of research behind it. Whether a synthetic pentapeptide applied to the skin surface can meaningfully replicate this process is a different question, and one the current evidence cannot definitively answer.
The Bottom Line
Matrixyl (pal-KTTKS) is a synthetic signal peptide derived from type I procollagen that stimulates collagen production in dermal fibroblasts through the matrikine signaling pathway. Two small clinical trials show wrinkle reduction at very low concentrations, but both have significant limitations including manufacturer funding and small sample sizes. The in vitro mechanism is well-supported; the translation to clinical skin improvement through topical application remains the weak link in the evidence chain.